Position in FLGT
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$358,135
+$2,786 QoQ
Shares Held
17,453
-21.9% QoQ
Ownership
0.063%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#72
of 142 holders
Holding Since
Jun 2023
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in FLGT Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Jun 30, 2026Headlands Technologies LLC holds $7,069,211 across 9 Diagnostics & Research names. FLGT ranks #6 (5.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TMO |
Thermo Fisher Scientific Inc.
|
6,280 | $3,148,540 | |
| 2 | NTRA |
Natera, Inc.
|
5,102 | $1,384,937 | |
| 3 | IDXX |
Idexx Laboratories Inc /De
|
2,133 | $1,122,896 | |
| 4 | DHR |
Danaher Corp /De/
|
2,440 | $464,771 | |
| 5 | RVTY |
Revvity, Inc.
|
3,330 | $370,495 | |
| 6 | FLGT |
Fulgent Genetics, Inc.
This page
|
17,453 | $358,135 | |
| 7 | OPK |
Opko Health, Inc.
|
107,989 | $161,983 | |
| 8 | MYGN |
Myriad Genetics Inc
|
10,062 | $57,454 |
All Filings in FLGT
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $358,135 | 17,453 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $355,349 | 22,349 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $316,448 | 12,046 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $214,541 | 9,493 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $291,242 | 14,650 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $118,992 | 7,041 | Shares | Sole | 2025-05-09 | |
| 2024-12-31 | $120,368 | 6,517 | Shares | Sole | 2025-02-12 | |
| 2024-06-30 | $981 | 50 | Shares | Sole | 2024-08-07 | |
| 2023-12-31 | $1,734 | 60 | Shares | Sole | 2024-02-02 | |
| 2023-09-30 | $10,883 | 407 | Shares | Sole | 2023-11-09 | |
| 2023-06-30 | $71,838 | 1,940 | Shares | Sole | 2023-08-03 | |
| No filing history on record for this holder in this stock. | ||||||